Abstract
In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses.
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alkynes
-
Antiviral Agents / therapeutic use*
-
Benzimidazoles / therapeutic use*
-
Benzoxazines / blood
-
Benzoxazines / metabolism*
-
Black or African American
-
Cohort Studies
-
Coinfection / drug therapy
-
Coinfection / ethnology
-
Coinfection / virology
-
Cyclopropanes
-
Cytochrome P-450 CYP2B6 / genetics*
-
Drug Therapy, Combination
-
Female
-
Fluorenes / therapeutic use*
-
Genome-Wide Association Study
-
Genotype
-
HIV Infections / drug therapy
-
HIV Infections / ethnology
-
Hepacivirus / drug effects
-
Hepatitis C / drug therapy*
-
Hepatitis C / ethnology
-
Hepatitis C / genetics
-
Humans
-
Male
-
Polymorphism, Single Nucleotide
-
Recurrence
-
Sofosbuvir / therapeutic use*
Substances
-
Alkynes
-
Antiviral Agents
-
Benzimidazoles
-
Benzoxazines
-
Cyclopropanes
-
Fluorenes
-
ledipasvir
-
CYP2B6 protein, human
-
Cytochrome P-450 CYP2B6
-
efavirenz
-
Sofosbuvir